NASDAQ:INMB - INmune Bio Stock Price, News & Analysis

$6.20
+0.01 (+0.16 %)
(As of 09/15/2019 04:00 PM ET)
Today's Range
$6.02
Now: $6.20
$6.32
50-Day Range
$5.29
MA: $6.88
$9.47
52-Week Range
$5.06
Now: $6.20
$11.50
Volume12,080 shs
Average Volume37,717 shs
Market Capitalization$66.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INMB
CUSIPN/A
CIKN/A
Phone858-964-3720

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.90 per share

Profitability

Miscellaneous

Employees3
Market Cap$66.71 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive INMB News and Ratings via Email

Sign-up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.


INmune Bio (NASDAQ:INMB) Frequently Asked Questions

What is INmune Bio's stock symbol?

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

How were INmune Bio's earnings last quarter?

INmune Bio Inc (NASDAQ:INMB) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.16. View INmune Bio's Earnings History.

When is INmune Bio's next earnings date?

INmune Bio is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for INmune Bio.

What price target have analysts set for INMB?

2 brokerages have issued twelve-month target prices for INmune Bio's stock. Their predictions range from $11.50 to $13.00. On average, they expect INmune Bio's stock price to reach $12.25 in the next twelve months. This suggests a possible upside of 97.6% from the stock's current price. View Analyst Price Targets for INmune Bio.

What is the consensus analysts' recommendation for INmune Bio?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for INmune Bio.

What are Wall Street analysts saying about INmune Bio stock?

Here are some recent quotes from research analysts about INmune Bio stock:
  • 1. HC Wainwright analysts commented, "We maintain our Buy rating of INMB and our 12-month price target of $11.50 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from 2030, assuming a 13% discount rate and a 0.5% terminal growth rate. We derive an rNPV of $345M for the products and add in cash and cash equivalents of $9.4M to arrive at a 12-month price target of $11.43 per diluted share, which we round to $11.50." (9/12/2019)
  • 2. Maxim Group analysts commented, "INmune Bio reported 2Q19 with operating expenses of ~$2M, partially offset by a $1.5M non-cash charge (waiver of common stock issuable); net loss was ($0.4M). The company ended the period with $9.4M in cash on the balance sheet. In addition, recall that as a result of the $1M grant from the Alzheimer’s foundation and also conducting trials abroad which comes with significant R&D reimbursement, the runway is further extended." (8/14/2019)

Has INmune Bio been receiving favorable news coverage?

Media stories about INMB stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. INmune Bio earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for INmune Bio.

Are investors shorting INmune Bio?

INmune Bio saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 5,900 shares, a decline of 16.9% from the July 31st total of 7,100 shares. Based on an average daily volume of 21,500 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.5% of the shares of the company are sold short. View INmune Bio's Current Options Chain.

Who are some of INmune Bio's key competitors?

What other stocks do shareholders of INmune Bio own?

Who are INmune Bio's key executives?

INmune Bio's management team includes the folowing people:
  • Dr. Raymond Joseph Tesi, Co-Founder, Pres, CEO & Director (Age 63)
  • Mr. David J. Moss M.B.A., CFO, Treasurer & Sec. (Age 49)
  • Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Chief Scientific Officer (Age 56)

When did INmune Bio's lock-up period expire?

INmune Bio's lock-up period expired on Monday, August 5th. INmune Bio had issued 1,020,560 shares in its initial public offering on February 4th. The total size of the offering was $8,164,480 based on an initial share price of $8.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are INmune Bio's major shareholders?

INmune Bio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.03%). Company insiders that own INmune Bio stock include David J Moss, Linda F Powers, Raymond Joseph Tesi and Scott Juda. View Institutional Ownership Trends for INmune Bio.

Which major investors are buying INmune Bio stock?

INMB stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have bought INmune Bio stock in the last two years include David J Moss, Linda F Powers, Raymond Joseph Tesi and Scott Juda. View Insider Buying and Selling for INmune Bio.

How do I buy shares of INmune Bio?

Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is INmune Bio's stock price today?

One share of INMB stock can currently be purchased for approximately $6.20.

How big of a company is INmune Bio?

INmune Bio has a market capitalization of $66.71 million. INmune Bio employs 3 workers across the globe.View Additional Information About INmune Bio.

What is INmune Bio's official website?

The official website for INmune Bio is http://www.inmunebio.com/.

How can I contact INmune Bio?

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at 858-964-3720 or via email at [email protected]


MarketBeat Community Rating for INmune Bio (NASDAQ INMB)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about INmune Bio and other stocks. Vote "Outperform" if you believe INMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel